Drugs in MeSH Category Antiparasitic Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes	9,233,117
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes	9,089,587
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes	10,206,939
Teva Pharms Usa	IVERMECTIN	ivermectin	CREAM;TOPICAL	210019-001	Sep 13, 2019	AB	RX	No	No
Zydus Lifesciences	IVERMECTIN	ivermectin	CREAM;TOPICAL	215210-001	Aug 2, 2022	AB	RX	No	No

Antiparasitic Agents Market Analysis and Financial Projection

The global antiparasitic drugs market is undergoing significant transformation, driven by evolving disease burdens, technological advancements, and shifting R&D priorities. Valued at $17.9 billion in 2023, the market is projected to grow at a 5.4% CAGR through 2032, reaching $38.20 billion[1][9]. This growth is fueled by rising parasitic infections affecting nearly 25% of the global population[11], particularly in tropical regions where malaria, soil-transmitted helminths, and neglected tropical diseases remain endemic.

Market Dynamics

Key Growth Drivers:

• Drug Resistance Challenges: Over 60% of malaria-endemic countries report artemisinin resistance[13], necessitating new therapeutic approaches
• Emerging Market Opportunities: Developing regions show 12% higher infection rates than developed nations[1], with improved healthcare access creating demand for affordable treatments
• Technological Innovations: Targeted therapies now account for 38% of R&D investments[5], focusing on molecular precision to combat resistant strains
• Public Health Initiatives: WHO's Expanded Special Project for NTDs has mobilized $780M+ since 2020 for drug distribution programs[9]

Market Segmentation (2023):	Category	Leading Segment	Market Share	Growth Driver
Drug Type	Anthelmintics	47%	High soil-transmitted helminth burden
Administration Route	Injectables	58%	Critical care requirements for severe infections
Distribution Channel	Hospital Pharmacies	63%	Complex dosing regimens for IV therapies
Geography	North America	37%	Advanced healthcare infrastructure

Patent Landscape Analysis

The antiparasitic patent field reveals distinct patterns:

1. Geographic Concentration:

   • US (42%) and China (29%) dominate filings[2]
   • EU institutions account for 18% of biocontrol patents[6]

2. Technology Focus:

   • 61% target protozoal diseases vs 39% helminthic[2]
   • Molecular-targeted therapies increased 140% since 2015[16]

Notable Patent Trends:

• Drug Repurposing: 22% of recent patents involve existing drugs like Gemfibrozil for Krabbe disease[12]
• Biocontrol Innovations: CNRS holds 14 patents for plant-based antiparasitic compounds[6]
• Resistance Breakthroughs: WO2021077102A1 details tubulin-binding compounds effective against drug-resistant Leishmania[16]

Strategic Challenges

1. R&D Bottlenecks: Only 3% of screened compounds reach clinical stages for NTDs[8]
2. Commercial Viability: NTD therapies average 11-year ROI cycles vs 6 years for oncology drugs[8]
3. IP Fragmentation: No single entity holds >33% of antiparasitic patents[2], complicating licensing

Future Outlook

The sector is pivoting toward:

1. Precision Therapies:
   • RNA interference treatments in Phase III trials show 92% efficacy against schistosomiasis[17]
2. Climate-Responsive Formulations:
   • Temperature-stable ivermectin variants extend shelf life by 300% in tropical conditions[13]
3. AI-Driven Discovery:
   • Machine learning models reduced lead compound identification time from 18 to 2.7 months[8]

"The next decade will see antiparasitics transition from broad-spectrum agents to tailored molecular interventions" - 2024 Global Pharma Innovation Report[5]

As vector-borne diseases expand into new regions due to climate change, the antiparasitic market must balance commercial realities with global health imperatives. Success will depend on cross-sector partnerships, with 78% of industry leaders prioritizing academic collaborations over in-house R&D[2][8].

References

1. https://www.polarismarketresearch.com/press-releases/antiparasitic-drugs-market
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC5686799/
3. https://pubmed.ncbi.nlm.nih.gov/22652215/
4. https://pubmed.ncbi.nlm.nih.gov/15363437/
5. https://www.globenewswire.com/news-release/2024/02/20/2832099/0/en/Antiparasitic-Drugs-Industry-Poised-For-Robust-Growth-Market-To-Grow-At-A-Rate-Of-More-Than-6-As-Per-The-Business-Research-Company-s-Antiparasitic-Drugs-Global-Market-Report-2024.html
6. https://www.wipo.int/web-publications/patent-landscape-report-agrifood/en/4-non-pesticide-pest-and-disease-management.html
7. https://pubmed.ncbi.nlm.nih.gov/8602186/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8703564/
9. https://www.grandviewresearch.com/industry-analysis/antiparasitic-drugs-market-report
10. https://kclpure.kcl.ac.uk/portal/files/253822283/Medical-Uses-of-Known-Products-V1-3.pdf
11. https://www.precedenceresearch.com/antiparasitic-drugs-market
12. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.1.0012
13. https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report
14. https://patents.google.com/patent/GB9315108D0/da
15. https://meshb.nlm.nih.gov/record/ui?ui=D000977
16. https://patents.google.com/patent/WO2021077102A1/en
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC8199835/
18. https://pubmed.ncbi.nlm.nih.gov/18991800/